- Pfizer has acquired NJ-based Innopharma for $225 million up front and $135 million in contingent milestone payments.
- Innopharma focuses on complex injectable delivery forms.
- Pfizer’s current Global Established Pharma (GEP) division includes Pfizer Injectables. The acquisition of Innopharma will allow Pfizer to strengthen this portion of the company.
Innopharma’s portfolio currently consists of 10 FDA-approved generics, 19 products that have been filed with the FDA, and more than 30 products that are in various stages of development. Most of the pipeline drugs are either injectables or ophthalmic products.
There are several important synergies that Pfizer Injectables can capitalize on from this acquisition. The division focuses on manufacturing, production, and sales of pharmaceutical and surgical products -- skills that it can apply to Innopharma's robust product pipeline, while also taking advantage of the latter company's deep reservoir of knowledge about addressing the challenges of complex manufacturing processes.